{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:02:33Z","timestamp":1762430553118},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":623,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Novartis, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.cct.2011.06.004","type":"journal-article","created":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T09:44:31Z","timestamp":1310118271000},"page":"818-828","source":"Crossref","is-referenced-by-count":20,"title":["Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD"],"prefix":"10.1016","volume":"32","author":[{"given":"Donald E.","family":"Stull","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingela","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupert","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gorana","family":"Capkun-Niggli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6 Suppl.","key":"10.1016\/j.cct.2011.06.004_bb0005","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/MLR.0b013e3181d99161","article-title":"Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects","volume":"48","author":"Kaplan","year":"2010","journal-title":"Med Care"},{"key":"10.1016\/j.cct.2011.06.004_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/gps.2723","article-title":"For the ADAPT Research Team. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial","author":"Leoutsakos","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"issue":"27","key":"10.1016\/j.cct.2011.06.004_bb0015","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1002\/sim.3721","article-title":"Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling","volume":"28","author":"Muthen","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.cct.2011.06.004_bb0020","series-title":"Causality and psychopathology: finding the determinants of disorders and their cures","first-page":"159","article-title":"General approaches to analysis of course: applying growth mixture modeling to randomized trials of depression medication","author":"Muth\u00e9n","year":"2011"},{"issue":"1","key":"10.1016\/j.cct.2011.06.004_bb0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11136-007-9290-5","article-title":"Analyzing growth and change: latent variable growth curve modeling with an application to clinical trials","volume":"17","author":"Stull","year":"2008","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.cct.2011.06.004_bb0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/biostatistics\/3.4.459","article-title":"General growth mixture modeling for randomized preventive interventions","volume":"3","author":"Muthen","year":"2002","journal-title":"Biostatistics"},{"issue":"7","key":"10.1016\/j.cct.2011.06.004_bb0035","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/thx.48.7.722","article-title":"Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD study group","volume":"48","author":"Kerstjens","year":"1993","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.cct.2011.06.004_bb0040","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1378\/chest.123.5.1441","article-title":"Long-term benefits with tiotropium in COPD patients with and without short = term bronchodilator responses","volume":"123","author":"Taskin","year":"2003","journal-title":"Chest"},{"issue":"9589","key":"10.1016\/j.cct.2011.06.004_bb0045","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0140-6736(07)61381-6","article-title":"What have we learned from large drug treatment trials in COPD?","volume":"370","author":"Calverley","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cct.2011.06.004_bb0050","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"176","author":"Rabe","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.cct.2011.06.004_bb0060","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.cct.2011.06.004_bb0070","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1183\/09031936.06.00145104","article-title":"Outcomes and markers in the assessment of chronic obstructive pulmonary disease","volume":"27","author":"Jones","year":"2006","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.cct.2011.06.004_bb0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1081\/COPD-200053377","article-title":"Minimal clinically important differences in COPD lung function","volume":"2","author":"Donohue","year":"2005","journal-title":"COPD"},{"issue":"3","key":"10.1016\/j.cct.2011.06.004_bb0080","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.rmed.2006.07.010","article-title":"Patient's perception of exacerbations of COPD\u2014the PERCEIVE study","volume":"101","author":"Miravitlles","year":"2007","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.cct.2011.06.004_bb0085","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.cct.2011.06.004_bb0090","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1378\/chest.93.3.580","article-title":"Evaluation of clinical methods for rating dyspnea","volume":"93","author":"Mahler","year":"1988","journal-title":"Chest"},{"issue":"Suppl. A","key":"10.1016\/j.cct.2011.06.004_bb0095","first-page":"11A","article-title":"Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease \u2014 2003","volume":"10","author":"Canadian Thoracic Society","year":"2003","journal-title":"Can Respir J"},{"issue":"8","key":"10.1016\/j.cct.2011.06.004_bb0100","first-page":"1040","article-title":"The 2007 GOLD Guidelines: a comprehensive care framework","volume":"54","author":"Gold","year":"2009","journal-title":"Respir Care"},{"key":"10.1016\/j.cct.2011.06.004_bb0105","series-title":"Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD)","author":"EMEA Committee for Proprietary Medicinal Products (CPMP)","year":"1999"},{"issue":"235","key":"10.1016\/j.cct.2011.06.004_bb0110","first-page":"65132","article-title":"Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims","volume":"74","year":"2009","journal-title":"Fed Regist"},{"issue":"6","key":"10.1016\/j.cct.2011.06.004_bb0115","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.pupt.2006.09.001","article-title":"Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial","volume":"20","author":"Beier","year":"2007","journal-title":"Pulm Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.cct.2011.06.004_bb0120","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.rmed.2008.02.001","article-title":"A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison","volume":"102","author":"Rennard","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.cct.2011.06.004_bb0125","series-title":"American Thoracic Society conference","article-title":"Sustained 24-h bronchodilation with indacaterol once-daily in COPD: a 26-week efficacy and safety study","year":"2009"},{"key":"10.1016\/j.cct.2011.06.004_bb0130","series-title":"Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation versus placebo and tiotropium","year":"2009"},{"key":"10.1016\/j.cct.2011.06.004_bb0135","series-title":"European Respiratory Society conference","article-title":"Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium","year":"2009"},{"key":"10.1016\/j.cct.2011.06.004_bb0140","series-title":"European Respiratory Society conference","article-title":"Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium","year":"2009"},{"key":"10.1016\/j.cct.2011.06.004_bb0145","article-title":"Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison","author":"Kornmann","year":"2010","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.cct.2011.06.004_bb0150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thx.2009.125435","article-title":"INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD","volume":"65","author":"Dahl","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.cct.2011.06.004_bb0155","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.200910-1500OC","article-title":"Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium","author":"Donohue","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.cct.2011.06.004_bb0160","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","article-title":"The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.cct.2011.06.004_bb0165","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.cct.2011.06.004_bb0170","doi-asserted-by":"crossref","first-page":"36s","DOI":"10.1183\/09031936.03.00078102","article-title":"The assessment of health status among patients with COPD","volume":"41","author":"Curtis","year":"2003","journal-title":"Eur Respir J Suppl"},{"key":"10.1016\/j.cct.2011.06.004_bb0175","series-title":"European Respiratory Society conference","article-title":"Indacaterol once-daily improves health-related quality of life (HRQOL) in COPD patients: a 52-week study","year":"2009"},{"issue":"12","key":"10.1016\/j.cct.2011.06.004_bb0180","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0895-4356(03)00115-X","article-title":"Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction","volume":"56","author":"Schunemann","year":"2003","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.cct.2011.06.004_bb0185","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/10705510709336735","article-title":"Performance of factor mixture models as a function of model size, covariate effects, and class-specific parameters","volume":"14","author":"Lubke","year":"2007","journal-title":"Structural Equation Modeling: A Multidisciplinary Journal"},{"key":"10.1016\/j.cct.2011.06.004_bb0190","series-title":"Mplus. Version 4.21","author":"Muth\u00e9n","year":"2007"},{"issue":"2","key":"10.1016\/j.cct.2011.06.004_bb0195","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/00273171003680245","article-title":"Detecting social desirability bias using factor mixture models","volume":"45","author":"Leite","year":"2010","journal-title":"Multivar Behav Res"},{"issue":"Information Age Publishing, Inc","key":"10.1016\/j.cct.2011.06.004_bb0200","first-page":"317","article-title":"Identifying the correct number of classes in growth mixture models","author":"Tofighi","year":"2008","journal-title":"Advances in latent variable mixture models"},{"issue":"4","key":"10.1016\/j.cct.2011.06.004_bb0205","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11136-009-9452-8","article-title":"Do not test for baseline imbalances unless they are known to be present?","volume":"18","author":"Berger","year":"2009","journal-title":"Qual Life Res"},{"key":"10.1016\/j.cct.2011.06.004_bb0210","series-title":"ISPOR 14th Annual International Meeting; 2009; Paris, France","article-title":"Uncovering heterogeneity in clinical studies: factor mixture models growth mixture models","author":"Stull","year":"2009"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714411001492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714411001492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T11:23:55Z","timestamp":1543663435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714411001492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1551714411001492"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2011.06.004","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}